Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain

Journal of Pain and Symptom Management

Volumn 21, Issue 2, 2001, Pages 129-143

  Neighbors, Deirdre M ^a,b   Bell, Timothy J ^a   Wilson, Jerome ^c   Dodd, Sheri L ^d  

^a RTI INTERNATIONAL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cost; Decision analysis; Morphine; Opioid; Oxycodone; QALY; Transdermal fentanyl; Utility

Indexed keywords

FENTANYL; MORPHINE SULFATE; OXYCODONE;

ARTICLE; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; COST UTILITY ANALYSIS; DECISION MAKING; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PAIN; PAIN ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RESPIRATION DEPRESSION;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; CHRONIC DISEASE; FENTANYL; HEALTH CARE COSTS; HUMANS; PAIN; PALLIATIVE CARE; SEVERITY OF ILLNESS INDEX;

EID: 0035133936     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(00)00247-5     Document Type: Article

References (29)

1. Direct conversion from oral morphine to transdermal fentanyl; a multicenter study in patients with cancer pain
2. Management of cancer-related pain with transdermal fentanyl
3. New approaches to pain control in patients with cancer
4. Guidelines for the clinical use of transdermal fentanyl
5. Withdrawal with transdermal fentanyl
6. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain; short- and long-term experiences in a prospective study of 39 patients
7. Transdermal fentanyl; seeding trial in patients with chronic cancer pain
8. Management of cancer pain with transdermal fentanyl; phase IV trial, University of Iowa
9. Transdermal fentanyl and respiratory depression
10. Gastrointestinal side effects diminishes after switch over from morphine to transdermal fentanyl
11. Transdermal fentanyl; clinical trial at the University of Colorado Health Sciences Center
12. Transdermal fentanyl versus sustained-release oral morphine in cancer pain; preference, efficacy, and quality of life
13. Duragesic (transdermal fentanyl) in hospice care
14. Long-term oral opioid therapy in patients with chronic nonmalignant pain
15. Chronic opioid therapy in nonmalignant pain
16. Fentanyl transdermal system; pain management at home
17. Transdermal fentanyl; a review of its pharmacological properties and therapeutic efficacy in pain control
18. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin
19. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
20. The costs of managing severe cancer pain and potential savings from transdermal administration
21. Valuing outcomes in health care; a comparison of willingness-to-pay and quality-adjusted life-years
22. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
23. Controlled-release oxycodone and morphine in cancer related pain
24. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
25. Transdermal fentanyl in the management of cancer pain in ambulatory patients; an open-label pilot study